Effect of butyrate-producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab.
Kazuhiro NousoShohei ShiotaRio FujitaAkiko WakutaKazuya KariyamaAtsushi HiraokaMasanori AtsukawaJoji TaniToshifumi TadaShinichiro NakamuraKazuto TajiriMasaki KaiboriMasashi HirookaEi ItobayashiSatoru KakizakiAtsushi NaganumaToru IshikawaTakeshi HatanakaShinya FukunishiKunihiko TsujiKazuhito KawataKoichi TakaguchiAkemi TsutsuiChikara OgawaHironori OchiYutaka YataHidekatsu KurodaHiroko IijimaTomomitsu MatonoNoritomo ShimadaSatoshi YasudaHidenori ToyodaTakashi Kumadanull nullPublished in: Cancer medicine (2023)
Butyrate-producing bacteria does not enhance the efficacy of atezolizumab-bevacizumab combination therapy in patients with HCC.